HINGE HEALTH INC.

Hinge Health significantly exceeded revenue expectations in the second quarter and reported strong operating metrics. The company raised its revenue forecast for the current fiscal year. Its strategic expansion into the gastrointestinal area underscores additional long-term scaling potential and triggered a sharp jump in the share price. » Plus sur finanzen.net

Hinge Health’s stock rose to an all-time high of $93.37, about 1% below its 52-week high. The shares gained roughly 60.55% over the past year; market capitalization is $7.25 billion with nearly 50% revenue growth in the last twelve months. Hinge Health beat expectations in the second quarter with earnings of $0.59 per share and revenue of $212.8 million (+53%), doubled operating income to $62 million and raised its 2026 guidance. The company is expanding via the acquisition of Cylinder Health for $105 million; several analysts subsequently raised price targets. » Plus sur de.investing.com

Hinge Health shares climbed to an all-time high of $91.54 and are currently at $91.51 with a market capitalization of $7.21 billion. Over the past year the stock rose 62.8%, gained 170% in the last six months and is up 92% year-to-date. Hinge Health beat expectations in the second quarter (EPS $0.59 vs. $0.13; revenue +53% to $212.8 million), raised its full-year guidance and announced the $105 million acquisition of Cylinder Health. Analysts raised price targets (including Truist $112, Citizens $107, Stifel $96), while InvestingPro warns of overvaluation and an overbought RSI. » Plus sur de.investing.com